"Designing Growth Strategies is in our DNA"

Gene Therapy Market Size, Share and Industry Analysis By Disease Indication (Cancer, Genetic disorders, Cardiovascular diseases, Ophthalmology, Neurological conditions) By Type of Vectors (Viral vectors, Non-viral vectors), By Type of Cells (Somatic cells, Germline cells), and Regional Forecast till 2026

Region : Global | Report ID: FBI100243 | Status : Ongoing



The U.S. Food and Drug Administration (FDA) defines human gene therapy as the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. The FDA approval of Kymriah for the treatment of paediatric and young adult patients with acute lymphoblastic leukaemia (ALL), Yescarta for the treatment of B-cell lymphoma and Luxturna for the treatment of children and adults with retinal dystrophy due to a mutation of the RPE65 gene in 2017 has encouraged many large life sciences companies to focus the development of gene therapy products, either through investment in research & development (R&D) or boosting their pipeline through acquisitions. For example, Novartis AG acquired AveXis, Inc. for $8.7 billion whereas Astellas Pharma Inc. acquired Quethera Ltd. in 2018.

The growth in the number of products in the advanced stages of R&D along with the focus on the treatment of rare diseases is anticipated to drive the gene therapy market size at a considerably fast rate. A study published by The Massachusetts Institute of Technology (MIT) has predicted that around 40 FDA-approved gene therapy products will be in the market by 2022.

To get information on various segments, share your queries with us

The factor that is expected to inhibit the growth of the market is the huge price tag associated with gene therapy products. For example, Kymriah is expected to cost patients around $475,000 for a treatment course. Regulatory and clinical hurdles might also impact the growth of the market due to delays in product approvals. 

Key Players Covered 

Some of the major companies that are present in the global gene therapy market research report are;

  • Pfizer Inc.,

  • Novartis AG,

  • Bayer AG,

  • Sanofi,

  • GlaxoSmithKline plc.,

  • Amgen Inc.,

  • Boehringer Ingelheim International GmbH,

  • UniQure N.V.,

  • Bluebird bio, Inc.,

  • Celgene Corporation,

  • Other Players  




By Disease Indication

  • Cancer

  • Genetic disorders

  • Cardiovascular diseases

  • Ophthalmology

  • Neurological conditions

  • Others

By Type of Vectors

  • Viral vectors

  • Non-viral vectors

By Type of Cells

  • Somatic cells

  • Germline cells

By Geography

  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


At present, cancer accounts for the largest proportion of the market and this is not expected to change in the forecast period based on MIT study, which predicted that out of the 40 FDA-approved gene therapy products by 2022, around half are expected to be in the oncology space. 

Key Insights

  • Pipeline analysis

  • Regulatory scenario for key countries

  • Reimbursement scenario for key countries

  • Key mergers and acquisitions

  • Key start-ups with their funding overview

  • Prevalence of diseases being treated by currently approved gene therapy products in key countries. 

Regional Analysis 

The global gene therapy market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe are the two largest markets for gene therapy at present and they are expected to account for a large proportion of the market in the forecast period as well. The world’s first gene therapy, Glybera, was approved in Europe in 2012 and the region had ten cell and gene therapies approved in 2018. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. AnGes MG, a biopharmaceutical start-up based in Japan, is expected to receive approval for a gene therapy product for the treatment of inadequate blood circulation in legs in the country in 2019. 

Key Industry Developments

  •  In February 2019, Sangamo Therapeutics, Inc. announced the FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease.

  • In November 2018, Novartis received approval from European Commission for Luxturna, a gene therapy to treat patients with vision loss due to a genetic mutation in both copies of the RPE65 gene

  • In 2018, FDA announced about their plan to speed up the approval path for certain gene therapies, especially products being developed for rare conditions.

  • In August 2017, the first gene therapy, Kymriah, for the treatment of lymphoblastic leukemia in pediatric and young adult populations was approved in the U.S. 

Gene Therapy Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017


  • 4850

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.